{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:48:28Z","timestamp":1790668108186,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178148","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:53:17Z","timestamp":1758055997000},"page":"178148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis"],"prefix":"10.1016","volume":"1006","author":[{"given":"Huimin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6739","authenticated-orcid":false,"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178148_bib1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.clnu.2017.09.028","article-title":"A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis","volume":"37","author":"Adiamah","year":"2018","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejphar.2025.178148_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40256-023-00621-5","article-title":"Safety and efficacy of Proprotein Convertase Subtilisin-Kexin type 9 inhibitors after Acute coronary syndrome: a meta-analysis of randomized controlled trials","volume":"24","author":"Atia","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ejphar.2025.178148_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20142012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178148_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2018.01.025","article-title":"Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps","volume":"130","author":"Baragetti","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.178148_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-Week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1042\/CS20130556","article-title":"Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein \u03b52","volume":"126","author":"Brouwers","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2025.178148_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1042\/CS20110129","article-title":"Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia","volume":"121","author":"Brouwers","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2025.178148_bib8","volume":"8","author":"Cao","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is Most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib10","first-page":"578","article-title":"Guidelines for diagnosis and treatment of acute pancreatitis in China (2021)","volume":"59","year":"2021","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"10.1016\/j.ejphar.2025.178148_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13863","article-title":"Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: the LIPID-REAL registry","volume":"52","author":"Cordero","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.178148_bib12","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2025.178148_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2018.03.013","article-title":"Beyond LDL: what role for PCSK9 in triglyceride-rich lipoprotein metabolism?","volume":"29","author":"Dijk","year":"2018","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2025.178148_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/0929867330666230228120601","article-title":"Efficacy and safety of alirocumab and evolocumab as Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) inhibitors in familial hypercholesterolemia: a systematic review and meta-analysis","volume":"31","author":"Ghasempour","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178148_bib15","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178148_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjcvp\/pvaa024","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis","volume":"7","author":"Guedeney","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejphar.2025.178148_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.25122\/jml-2021-0210","article-title":"The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression","volume":"16","author":"Hadi","year":"2023","journal-title":"Journal of Medicine and Life"},{"key":"10.1016\/j.ejphar.2025.178148_bib18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jacl.2019.09.005","article-title":"A 16-year trend of etiology in acute pancreatitis: the increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis","volume":"13","author":"Jin","year":"2019","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.ejphar.2025.178148_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","article-title":"PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells","volume":"227","author":"Levy","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2025.178148_bib20","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.3748\/wjg.v28.i29.3946","article-title":"Incidence and clinical characteristics of hypertriglyceridemic acute pancreatitis: a retrospective single-center study","volume":"28","author":"Lin","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.178148_bib21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/00365521.2024.2342406","article-title":"The effect of serum triglyceride levels and different lipid-lowering methods on the prognosis of hypertriglyceridemic acute pancreatitis: a single-center 12-year retrospective study by propensity score matching","volume":"59","author":"Liu","year":"2024","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.178148_bib22","first-page":"356","article-title":"PCSK9 inhibitors in multi-branch lesions in coronary artery disease with substandard lipid-lowering effects","volume":"30","author":"Lu","year":"2024","journal-title":"Alternative Ther. Health Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.pan.2020.03.018","article-title":"Hypertriglyceridemia-induced acute pancreatitis: a prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases","volume":"20","author":"Mosztbacher","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejphar.2025.178148_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2025.178148_bib25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"173","author":"Murphy","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/17474124.2021.1924058","article-title":"Ranson score to stratify severity in Acute Pancreatitis remains valid - old is gold","volume":"15","author":"Ong","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ejphar.2025.178148_bib27","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations inPCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2025.178148_bib28","first-page":"1141","article-title":"The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels","volume":"40","author":"Peng","year":"2020","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.ejphar.2025.178148_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/011573403X343784241115055037","article-title":"Successful use of Proprotein Convertase Subtilisin\/Kexin type 9 inhibitors in hypertriglyceridemia-induced acute pancreatitis: a case report","volume":"21","author":"Qi","year":"2025","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.ejphar.2025.178148_bib46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178148_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178148_bib31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.178148_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10557-016-6666-1","article-title":"Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia","volume":"30","author":"Rosenson","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2025.178148_bib33","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.36740\/WLek202112111","article-title":"The effect of evolocumab alone and in combination with atorvastatin on lipid profile","volume":"74","author":"Saud","year":"2021","journal-title":"Wiad. Lek."},{"key":"10.1016\/j.ejphar.2025.178148_bib34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.hpb.2023.05.006","article-title":"Hypertriglyceridemia as a risk factor for complications of acute pancreatitis and the development of a severity prediction model","volume":"25","author":"Song","year":"2023","journal-title":"HPB : the official journal of the International Hepato Pancreato Biliary Association"},{"key":"10.1016\/j.ejphar.2025.178148_bib35","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0735-1097(16)31867-8","article-title":"PCSK9 inhibition-mediated reduction IN triglyceride with evolocumab IS related to baseline triglyceride levels: an analysIS from 1791 patients","volume":"67","author":"Stein","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178148_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.14309\/ajg.0000000000002645","article-title":"American college of gastroenterology guidelines: management of acute pancreatitis","volume":"119","author":"Tenner","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.178148_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: current status, controversies, and future directions","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038265","article-title":"Association of admission serum triglyceride levels with intensive care unit hospitalization rates in acute pancreatitis patients: a retrospective study","volume":"103","author":"Wen","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2025.178148_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11883-018-0720-3","article-title":"Evolocumab: considerations for the management of hyperlipidemia","volume":"20","author":"Wiggins","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ejphar.2025.178148_bib40","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1136\/gut.2008.152702","article-title":"The early prediction of mortality in acute pancreatitis: a large population-based study","volume":"57","author":"Wu","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178148_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejphar.2025.178148_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131775","article-title":"The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: a systematic review and meta-analysis","volume":"399","author":"Yifan","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178148_bib43","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.4103\/0366-6999.161361","article-title":"Clinical study of 224 patients with Hypertriglyceridemia pancreatitis","volume":"128","author":"Zhang","year":"2015","journal-title":"Chin. Med. J. (Peking)"},{"key":"10.1016\/j.ejphar.2025.178148_bib44","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12916-024-03755-8","article-title":"Triglyceride-lowering therapies in hypertriglyceridemia-associated acute pancreatitis in China: a multicentre prospective cohort study","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.ejphar.2025.178148_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12944-024-02057-5","article-title":"Analysis of the clinical profile and treatment efficiency of hyperlipidemic acute pancreatitis","volume":"23","author":"Zhou","year":"2024","journal-title":"Lipids Health Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:38:00Z","timestamp":1780202280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"alternative-id":["S0014299925009021"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178148","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178148"}}